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Abstract 
Satisfactory results have not yet been obtained in therapy for secondary prevention in 
ischemic stroke patients with antiphospholipid syndrome (APS). We therefore compared 
single antiplatelet therapy and a combination of antiplatelet and anticoagulation therapy for 
secondary prevention in ischemic stroke patients with APS.   
The subjects were 20 ischemic stroke patients with antiphospholipid antibody, 13 with pri-
mary antiphospholipid syndrome and 7 with SLE-related antiphospholipid syndrome. Diag-
nosis of APS was based on the 2006 Sydney criteria. Eligible patients were randomly assigned 
to either single antiplatelet therapy (aspirin 100 mg) or a combination of antiplatelet and an-
ticoagulation therapy (target INR: 2.0-3.0; mean 2.4±0.3) for the secondary prevention of 
stroke according to a double-blind protocol. There was no significant difference between 
the two groups in age, gender, NIH Stroke Scale on admission, mRS at discharge, or rate of 
hypertension, diabetes mellitus, hyperlipidemia, or cardiac disease. We obtained Kap-
lan-Meier survival curves for each treatment. The primary outcome was the occurrence of 
stroke. The mean follow-up time was 3.9±2.0 years. The cumulative incidence of stroke in 
patients with single antiplatelet treatment was statistically significantly higher than that in 
patients receiving the combination of antiplatelet and anticoagulation therapy (log-rank test, 
p-value=0.026). The incidence of hemorrhagic complications was similar in the two groups. 
The recent APASS study did not show any difference in effectiveness for secondary preven-
tion between single antiplatelet (aspirin) and single anticoagulant (warfarin) therapy. Our 
results indicate that combination therapy may be more effective in APS-related ischemic 
stroke.  
Key words: antiphospholipid syndrome, APS-related ischemic stroke, single antiplatelet therapy, 
combination therapy, Kaplan-Meier survival curves.   
Introduction 
Antiphospholipid syndrome (APS) [1] is a 
common autoimmune prothrombotic condition char-
acterized by arterial and venous thrombosis and 
pregnancy morbidity, associated with persistently 
positive anticardiolipin antibodies (aCL) and/or lu-
pus anticoagulant (LA) [2]. Concerning therapy, sat-
isfactory results have not yet been obtained in therapy 
for secondary prevention in ischemic stroke patients Int. J. Med. Sci. 2010, 7 
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with APS. We therefore compared single antiplatelet 
therapy and a combination of antiplatelet and anti-
coagulation therapy for secondary prevention in 
ischemic stroke patients with APS. According to the 
guidelines of the American Heart Association 
(APASS) [3] for prevention of stroke in patients with 
ischemic stroke or transient ischemic attack and with 
antiphospholipid antibodies (aPL), antiplatelet ther-
apy is reasonable for cases of cryptogenic ischemic 
stroke or TIA with positive aPL. On the other hand, 
oral anticoagulation with a target INR of 2 to 3 [4] is 
reasonable for patients with ischemic stroke or TIA 
who meet the criteria for APS with venous and arte-
rial occlusive disease in multiple organs, miscarriages, 
and livedo reticularis.   
Materials and Methods   
We focused on the secondary prevention of 
stroke with APS, and compared single antiplatelet 
therapy and a combination of antiplatelet and anti-
coagulation therapy in ischemic stroke patients with 
APS. The subjects were 20 ischemic stroke patients 
with antiphospholipid antibody (10 males and 10 fe-
males, mean age 48 years), who were hospitalized 
between October 2002 and November 2004.   
They consisted of 13 with primary antiphos-
pholipid syndrome and 7 with SLE-related an-
tiphospholipid syndrome. Diagnosis of APS was 
based on the 2006 Sydney criteria [5]. Only patients 
with positive IgG beta 2 glycoprotein I (beta 
2-GPI)-dependent anticardiolipin antibody and/or 
lupus anticoagulant, present on two or more occa-
sions, six weeks or more apart, were selected. Eligible 
patients were randomly assigned to either single an-
tiplatelet therapy (aspirin 100 mg) [6] or a combina-
tion of antiplatelet and anticoagulation therapy (target 
INR: 2.0-3.0; mean 2.4± 0.3) for the secondary preven-
tion of stroke, according to a double-blind protocol [3, 
7]. The purpose of the present study was to examine 
the effects of these regimens on recurrence of stroke. 
So, the primary endpoint was occurrence of stroke.  
This study was approved by the ethics commit-
tee of Tokai University, and prior informed consent 
was obtained from all patients who were eligible to 
participate. Randomization was performed using a 
randomly generated score.  
 
Results  
Table 1 shows the background of the two groups. 
There was no significant difference between the two 
groups in age, gender, NIH Stroke Scale on admis-
sion, modified Rankin scale (mRS) at discharge, or 
rates of hypertension, diabetes mellitus, hyperlipi-
demia, and cardiac disease. Transthoracic cardiac 
echo findings were available for 15 patients. The 
echocardiograms detected three mitral valve abnor-
malities, but these were not thought to be potential 
embolic sources. Two of these patients were random-
ized to the combination therapy group, and the other 
to the single modality group.  
Kaplan-Meier survival curves are shown in Fig-
ure 1. The mean follow-up time was 3.9±2.0 years. The 
cumulative incidence of stroke in patients with single 
antiplatelet treatment was higher than that in patients 
receiving the combination of antiplatelet and antico-
agulation therapy (log-rank test, p-value = 0.026). This 
difference is statistically significant. However, the 
patient who had recurrent thrombotic infarction in the 
combination of antiplatelet and anticoagulation ther-
apy group showed an INR before the recurrence of 
2.0, so the possibility of inadequate treatment can not 
be ruled out.  
 
Table 1. Baseline characteristics of patients.  
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Figure 1. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for 
secondary prevention in ischemic stroke patients with antiphospholipid syndrome.  
 




Next, we examined hemorrhagic complications 
in both groups. One minor cerebral hemorrhage was 
noted in the single antiplatelet therapy group, and 
one subcutaneous hemorrhage was found in the 
combination therapy group. As for the patient in the 
single antiplatelet therapy group who developed 
cerebral hemorrhage, magnetic resonance angiogra-
phy of the head showed no apparent aneurysm that 
might have resulted in hemorrhage. The patient was 
treated for hypertension, but had no other concurrent 
conditions. The blood pressure, at least on outpatient 
visits, had been stable. We did not encounter gastro-
intestinal bleeding. The incidence of hemorrhagic 
complications was similar in the two groups (Table 2).   
Discussion  
There is still debate as to which therapy is the 
most effective for secondary prevention of stroke with 
APS [4, 8, 9, 10] and concerning the relationship be-
tween APS and stroke. It is generally accepted that 
aPL is an independent risk factor for initial ischemic 
stroke in young adults [11, 12].  
Treatment to prevent recurrent stroke and other 
thrombotic events in APS patients has been reviewed 
[13]. Two groups have retrospective data to suggest 
that high-intensity warfarin treatment is associated 
with a better outcome in selected cohorts with various 
types of thrombotic events [6]. Khamashta [14] re-
ported that high-intensity warfarin (INR over 3.0) 
with or without low-dose aspirin (75 mg/day) was 
significantly more effective than low-intensity war-
farin (INR under 3.0) with or without low-dose aspi-
rin, or treatment with aspirin alone, in preventing 
further thrombotic events. Crowther [7] recently re-
ported the results of the first randomized, dou-
ble-blind, controlled trial of two different intensities 
of warfarin treatment on the prevention of recurrent 
thrombotic events in patients with APS. The 
high-intensity warfarin treatment was no more effec-
tive than moderate-intensity treatment in preventing 
recurrent thrombotic events.  
The APASS study [3] was the first prospective 
study of the role of aPL in recurrent ischemic stroke, 
in collaboration with the WAPS group [8]. This study 
did not show any difference in effectiveness for sec-
ondary prevention between single antiplatelet (aspi-
rin) and single anticoagulant (warfarin) therapy. 
Derksen [15] examined the effect of low-dose aspirin 
after first ischemic stroke associated with aPL. During 
about 9 years of follow-up, 2 of 9 patients had a re-Int. J. Med. Sci. 2010, 7 
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current stroke. Recurrent stroke rate per 100 pa-
tient-years on aspirin was only 3.5. But, we think sin-
gle antiplatelet therapy may be less effective for the 
secondary prevention of stroke than the combination 
of antiplatelet and anticoagulant therapy. We have 
examined endothelial function in patients with APS. 
Although protein C is activated on endothelial cells 
[16], we found that serum obtained from patients with 
positive IgG cardiolipin antibodies interfered with 
protein C activation [2]. Protein C activation is dis-
turbed in patients with APS [17]. Since protein C is 
closely associated with factor VIII and factor V, this 
result suggests that the coagulation system is im-
paired in patients with APS, and so anticoagulant 
could be effective. Aspirin influences endothelial 
function, and although the effect may be 
dose-dependent, the dose of 100 mg may be sufficient 
to improve endothelial function.  
There are some important limitations to be con-
sidered. First, diagnosis of APS in WAPS [8] was not 
based on the 2006 Sydney criteria [5]. As only a single 
measurement of anticardiolipin antibody and LA was 
obtained, cases with IgG beta-2 GPI non-dependent 
cardiolipin antibody were included. Second, the av-
erage age of patients (63 years) was significantly older 
than that in typical APS studies (34 years). Third, the 
target INR in WAPS [8] was for cardiogenic stroke 
caused by non-valvular Af. The dosage of aspirin in 
WAPS [8] was 325 mg. Currently, the recommended 
dosage of aspirin is only 75-150 mg. Treatment rec-
ommendations in this study were based on secondary 
prevention of ischemic stroke in patients without as-
sociated aPL. The patients in our study were selected 
according to the Sydney criteria [5] of APS and the 
average age was consistent with that in typical APS 
patients.  
There have not been any previous studies deal-
ing with the combination of antiplatelet and antico-
agulant therapy for ischemic stroke patients with APS 
based on the strict Sydney criteria [5]. One reason may 
be that patients with stroke complicated with APS are 
rather rare compared with patients with uncompli-
cated stroke, and this is also the reason why the 
number of patients in this study was quite small. 
Nevertheless our results seem promising, and a larger 
study with more patients would be warranted.  
Conclusion  
Our results indicate that a combination of anti-
platelet and anticoagulation therapy may be more 
effective than single antiplatelet therapy for secon-
dary prevention in ischemic stroke patients with APS.  
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